Morphosys AG - ADR

MorphoSys AG operates as a commercial-stage biopharmaceutical company. It uses groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients. The firm also engages in the development and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MorphoSys AG is a biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.

Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company's third clinical program to receive Fast Track designation PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tulmimetostat, the company's investigational next-generation dual inhibitor of EZH2 and EZH1, for the treatment of patients with advanced, recurrent or metastatic endometrial cancer harboring AT-rich interacting domain containing protein 1A (ARID1A) mutations and who have progressed on at least one prior line of treatment. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines intended to treat serious conditions and potentially address an unmet medical need, with the goal of getting these important, new therapies to patients earlier.

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

MorphoSys' Q2 2023 earnings exceeded expectations, with Monjuvi sales reaching $23.6m and an operational loss improvement. The company has a solid cash reserve of approximately EUR680m, providing a cash runway for 1-2 years. The upcoming topline data for the pelabresib P3 MANIFEST-2 study is a promising catalyst for stock performance.

MorphoSys: Pelabresib Data Coming Out Soon, More Room To Run

MorphoSys AG (NASDAQ:MOR ) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Julia Neugebauer – Head of Investor Relations Jean-Paul Kress – Chief Executive Officer Tim Demuth – Chief Research and Development Officer Lucy Crabtree – Chief Financial Officer Conference Call Participants Xian Deng – UBS Derek Archila – Wells Fargo Jason Butler – JMP James Quigley – Morgan Stanley Manos Mastorakis – Deutsche Bank Rajan Sharma – Goldman Sachs Ingrid Gafanhao – Bryan Garnier Operator Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the MorphoSys Second Quarter and First Half 2023 Financial Results.

MorphoSys AG (MOR) Q2 2023 Earnings Call Transcript

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the second quarter and first half year of 2023. "With topline data from the pivotal MANIFEST-2 trial now expected by year's end, we hear increased excitement from physician and patient communities around pelabresib as a potential first-line treatment for myelofibrosis. We are also seeing evidence of possible clinical benefit with pelabresib in other myeloid diseases, with new proof-of-concept data.

MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results

Sales beat: Despite Monjuvi's setbacks, MorphoSys exceeds Q1 2023 sales expectations with €62.3m and robust 11% YoY US growth. Pelabresib Potential: Accelerated MANIFEST-2 Pelabresib data readout could be a key catalyst, promising MF candidate with potentially substantial disease-modifying efficacy.

MorphoSys: Morphing Prospects, Q1 2023, Rising From The Ashes

MorphoSys AG (NASDAQ:MOR ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Julia Neugebauer - Vice President, Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Development Officer Joe Horvat - General Manager MorphoSys US Conference Call Participants Jason Butler - JMP Securities James Quigley - Morgan Stanley Zain Ebrahim - JPMorgan Vineet Agrawal - Citi Operator Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the First Quarter Interim Statement 2023 of MorphoSys.

MorphoSys AG (MOR) Q1 2023 Earnings Call Transcript

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023. “We had a strong first quarter, marked by numerous achievements. Most importantly, we completed enrollment of our Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis ahead of schedule. As a result, the topline data from the trial are now expected by the end of 2023, months earlier than previously anticipated,” said Jean-Paul Kress, M.D., Chief Executive Of.

MorphoSys AG Reports First Quarter 2023 Financial Results

Conference Call Alert MUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on May 4, 2023 at 02:00 pm CEST (01:00 pm BST; 08:00 am EDT) to present the results for the first quarter 2023 and provide an outlook for 2023.

Invitation to MorphoSys' First Quarter 2023 Financial Results Conference Call on May 4, 2023

MorphoSys completed enrollment for MANIFEST-2, a Phase 3 study exploring the safety and efficacy of pelabresib in combination with ruxolitinib for JAK inhibitor-naïve patients with myelofibrosis. The topline data of the MANIFEST-2 is expected by the end of 2023 (previously expected in 1H 2024).

MorphoSys: Pelabresib Data Expected In Year-End 2023, Upgrading To A Buy

Certara

CRISPR Therapeutics

Incyte

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

MorphoSys had said it planned to cut preclinical programs and trim its workforce. The company said it expected top-line results for a myelofibrosis drug later this year.

Why Shares of MorphoSys Are Up Wednesday

MorphoSys AG (NASDAQ:MOR ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Julia Neugebauer - Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Development Officer Sung Lee - Chief Financial Officer Joe Horvat - General Manager MorphoSys US Conference Call Participants James Quigley - Morgan Stanley James Gordon - J.P. Morgan Rajan Sharma - Goldman Sachs Suzanne van Voorthuizen - Kempen & Co Mohamad Vaseghi - Frankfurt Main Research Julia Neugebauer Ladies and gentlemen, good afternoon and good morning.

MorphoSys AG (MOR) Q4 2022 Earnings Call Transcript

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022. “2022 was a defining year for MorphoSys. We made advances in our pipeline by progressing our Phase 3 clinical trials, including pelabresib in myelofibrosis and tafasitamab in lymphomas. We also out-licensed highly promising, early and mid-stage product candidates, enabling us to concentrate exclusively on our work in oncology,” said Jean-Paul Kress, M.D.

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 9, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the financial year 2022 on March 15, 2023 at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 16, 2023 at 01:00 pm CET (12:00 pm GMT; 8:00 am EDT) to present the results for the financial year 2022 and provide an outlook for 2023.

Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023

MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) (the "Company") today announces that it will stop work and operations on its pre-clinical research programs to optimize its cost structure. As a result, MorphoSys will reduce its workforce at the Company's headquarters in Planegg, Germany, by approximately 17%.

Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters

MUNICH, GERMANY / ACCESSWIRE / March 2, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the company will stop work and operations on its pre-clinical research programs to optimize its cost structure. While the data from these pre-clinical programs are promising, MorphoSys would need to make substantial investments to bring these programs into the clinic.

MorphoSys Stops Work and Operations on Pre-Clinical Research Programs

MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's two key value drivers are a) monjuvi and b) pelabresib.

MorphoSys: Negative Enterprise Value Biotech, But Lack Of Near-Term Catalyst

MUNICH, GERMANY / ACCESSWIRE / January 9, 2023 / MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study - a global, randomized, double-blind clinical trial exploring pelabresib, an investigational BET inhibitor, in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis - are expected to be available in early 2024. The company previously communicated that these data were expected in the first half of 2024.

MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys caps off a year of bad news with the departure of its CFO. With gantenerumab done for now, the key P&L driver will be Monjuvi, a product that had consistently disappointed post-launch.

MorphoSys AG: Staying On The Sidelines

Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million ( € 84.9 million) Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million Preliminary unaudited financial liability from the collaboration with Incyte of approximately € 220 million which represents a reduction of € 360 million MUNICH, GERMANY / ACCESSWIRE / January 5, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary Monjuvi ® U.S. net product sales for the full year of 2022 and provided its financial guidance for 2023. In this context, MorphoSys reduced its financial liability from the collaboration with Incyte and credited finance income accordingly.

MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 28, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) publishes its financial calendar dates for the year 2023: Publication of Interim Statement / Report Conference Call Year-End Results 2022 March 15, 2023 // 9:00 pm CET(4:00 pm EDT; 8:00 pm GMT) March 16, 2023 // 1:00 pm CET(8:00 am EDT; 12:00 pm GMT) First Quarter Interim Statement 2023 May 3, 2023 // 10:00 pm CEST(4:00 pm EDT; 9:00 pm BST) May 4, 2023 // 2:00 pm CEST(8:00 am EDT; 1:00 pm BST) Half-Year Report 2023 August 9, 2023 // 10:00 pm CEST(4:00 pm EDT; 9:00 pm BST) August 10, 2023 // 2:00 pm CEST (8:00 am EDT; 1:00 pm BST) Third Quarter Interim Statement 2023 Nov. 15, 2023 // 10:00 pm CET(4:00 pm EST; 9:00 pm GMT) Nov. 16, 2023 // 2:00 pm CET(8:00 am EST; 1:00 pm GMT) Annual General Meeting May 17, 2023 Please visit our corporate website to import the dates into a calender via the following link: https://www.morphosys.com/en/all-events-conferences About MorphoSys: At MorphoSys, we are driven by our mission: More life for people with cancer. As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.

MorphoSys AG: Financial Calendar 2023

MorphoSys AG (NASDAQ:MOR ) Q3 2022 Earnings Conference Call November 17, 2022 8:00 AM ET Company Participants Julia Neugebauer - Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Joe Horvat - US General Manager Tim Demuth - Chief Research & Development Officer Sung Lee - Chief Financial Officer Conference Call Participants James Quigley - Morgan Stanley Roy Buchanan - JMP Securities James Gordon - JPMorgan Victor Floc'h - Stifel Suzanne van Voorthuizen - Kempen Vineet Agrawal - Citi Operator Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining the Third Quarter 2022 Financial Results Conference Call of MorphoSys.

MorphoSys AG (MOR) Q3 2022 Earnings Call Transcript

PLANEGG, Germany--( BUSINESS WIRE )--Conference call and webcast (in English) tomorrow, November 17, 2022, at 2:00pm CET (1pm GMT/8:00am ET)

MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

Roche Holding AG

German-listed shares of MorphoSys MOR, -31.96% MOR, +2.44% lost a third of their value on Monday after its partner Roche said an Alzheimer drug trial failed. Roche ROG, -3.76% slumped 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia did not meet their primary endpoint of slowing clinical decline.

MorphoSys shares plunge after partner Roche says Alzheimer's drug trials didn't meet goals

GRADUATE studies did not meet primary endpoint PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 14, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer's disease (AD). The studies did not meet their primary endpoint of slowing clinical decline.

News for Morphosys AG - ADR Stock (MOR)